2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
09:30 a.m. - 11:00 a.m.
MCCNO - Hall C
This session surveys the latest early-phase clinical data shaping the treatment landscape for chronic myelomonocytic leukemia (CMML), higher-risk myelodysplastic syndromes (MDS), and MDS/MPN overlap disorders. Presentations span first-in-human results for a novel CCR2-targeting cytotoxicity chimera, combination regimens pairing hypomethylating agents with venetoclax and other cytotoxic or immune-targeting partners (anti-CD47, anti-IL1RAP), and an all-oral treatment approach for MDS/MPN overlap syndromes. A pediatric-focused study extends the discussion to secondary myeloid neoplasms. Together, these studies reflect the field's ongoing shift toward targeted and combination-based strategies aimed at improving outcomes across this heterogeneous group of hard-to-treat myeloid malignancies.
Treatment Considerations, Combination Therapy, Drug Development, Biological Therapies, Immunotherapy, Diseases, Bone Marrow Failure Syndromes, Inherited Marrow Failure Syndromes, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Research, AML, MDS, MPN, CMML, Clinical Research, Clinical Trials, Study Population, Human, Adult
PAPER

531 Early safety and efficacy of IL1RAP antibody, nadunolimab in combination with azacitidine with or without venetoclax in patients with higher-risk MDS and relapsed/refractory AML: Results from a phase 1b/2a trial

Gautam Borthakur, MD, Helena Agerstam, MD2, Guillermo Montalban-Bravo, MD3, Maro Ohanian, DO4, Yesid Alvarado Valero, MD5, Abhishek Maiti, MBBS6, Naveen Pemmaraju, MD7, Ian Bouligny, M.D.8, Thoas Fioretos, Professor9, Guillermo Garcia-Manero, MD10
1 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
2 Lund University, Lund, Sweden, Lund, Sweden
3 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
4 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
5 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
6 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
7 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
8 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
9 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
10 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Background: Interleukin-1 receptor accessory protein (IL1RAP) is aberrantly expressed on leukemia stem cells (LSC) in acute myeloid leukemia (AML) and higher-risk myelodysplastic syndrome (MDS) and participates in interleukin-1 signaling. Nadunolimab is an IL1RAP-targeting antibody designed to induce antibody-dependent cellular cytotoxicity and inhibit interleukin-1 alpha/beta signaling. We report initial safety, efficacy and recommended phase 2 dose (RP2D) from an ongoing phase 1b/2a study of nadunolimab combined with azacitidine, with venetoclax in relapsed/refractory (R/R) AML and without venetoclax in higher-risk MDS (NCT06548230).

Methods: This 2-arm study uses a 3+3 dose-escalation lead-in evaluating 2 dose levels of nadunolimab (1 mg/kg and 2.5 mg/kg) in each arm, with standard dosing of azacitidine and venetoclax. Arm 1 is enrolling patients with Revised International Prognostic Scoring System (IPSS-R) intermediate/high/very-high-risk MDS who are untreated or have received up to 2 prior therapies. Untreated patients are required to have high-risk cytogenetics or mutations and unlikely to achieve a robust response to azacitidine alone. Arm 2 is enrolling patients with European LeukemiaNet (ELN) 2022-defined R/R AML receiving first or second salvage therapy, including patients with hypomethylating agent-treated MDS or chronic myelomonocytic leukemia who progressed to AML. In cycle 1, both arms receive nadunolimab on days 1, 8, and 21 and azacitidine on days 8-14; patients with AML also receive venetoclax on days 8-35. Thus, cycle 1 incorporates a 7-day nadunolimab monotherapy window (days 1-7), enabling assessment of early pharmacodynamic and cellular effects attributable to nadunolimab alone. From cycle 2, 28-day cycles comprise nadunolimab on days 1 and 14 and azacitidine on days 1-7; patients with AML receive venetoclax on days 1-21. Responses are categorized using International Working Group 2023 criteria for MDS and ELN 2017 criteria for AML. Translational studies include multi-dimensional flow cytometry, single-cell RNA sequencing, cytokine profiling, and broad gene panel analysis.

Results: Twenty-two patients have been enrolled (Data cut-off: June 30th, 2026); 3 patients in each arm received dose level 1 and the remaining patients received dose level 2. Nadunolimab 2.5 mg/kg was selected as RP2D in combination with azacitidine with or without venetoclax. Nineteen patients completed at least 1 cycle and are evaluable (MDS, n=10; AML, n=9). Median age was 72 years (range, 38-86), and 14 patients (74%) were male.

Among patients with MDS (untreated, n =9), IPSS-R risk was intermediate in 5, high in 4, and very high in 1; 4 had TP53 mutations and 5 had ASXL1 and/or RUNX1/GATA2 mutations. Seven of 10 patients (70%) achieved a response (CR, n=2; CRh, n=2; and CR with unilineage hematologic improvement [CRuni], n=3). Two additional subjects, without progression, are continuing therapy after C1 and 1 discontinued because of progressive disease.

All patients with AML (median number of prior therapies=2) had adverse-risk disease; 3 had MECOM rearrangements and 1 had a TP53 mutation. Three of 9 patients with AML (33%) responded: 1 achieved complete remission (CR), 1 CR with partial hematologic recovery (CRh) and 1 achieved a morphologic leukemia-free state (MLFS). One patient with MECOM-rearranged AML who was refractory to 1 cycle of FLAG-IDA achieved CRh and proceeded to stem cell transplantation. A patient with secondary AML previously treated with lenalidomide remains in CR, whereas a patient with STAG2- and RUNX1-mutated AML after 2 prior lines achieved MLFS and progressed after cycle 3.

Reported grade 3/4 events were neutropenia (n=11), thrombocytopenia (n=5), infections (n=5; including 1 enterocolitis and 1 pneumonia), infusion-related reaction (n=1), and subdural bleeding (n=1). The infusion-related reaction was likely related to nadunolimab; all other listed grade 3/4 events were considered unlikely related to nadunolimab. Enrollment and translational studies are ongoing.

Conclusions: Initial results demonstrate acceptable safety profile and promising clinical activity of nadunolimab-based combinations in both higher-risk MDS and adverse-risk R/R AML, including responses in molecularly high-risk disease. Most grade 3/4 adverse events were considered unlikely related to nadunolimab. These findings support continued enrollment in phase 2a expansion and planned biomarker studies.

Gautam Borthakur, MD: Ubix Therapeutics - Research Funding; Polaris Pharmaceuticals - Research Funding; Epigenetix - Research Funding; Astex Pharmaceuticals - Research Funding; Aptevo Therapeutics - Research Funding; Lava Therapeutics - Consultancy (Includes expert testimony); AbbVie - Consultancy (Includes expert testimony)